Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 16/20 | 0.65 |
| ▸ | ACE2 | Q9BYF1 | 13/20 | 0.65 |
| ▸ | ACE | P12821 | 13/20 | 0.65 |
| ▸ | CPA1 | P15085 | 11/20 | 0.65 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.57 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19888359 | 1.00 | MME (0.65) | MMEACE2ACECPA1ITGA4 | |
| SCHEMBL2720887 | 0.97 | MME (0.61) | MMEACE2ACECPA1 | |
| Benzene SCHEMBL27550555 | 0.92 | MME (0.59) | MMEACE2ACECPA1 | |
| Benzene SCHEMBL27550557 | 0.92 | MME (0.59) | MMEACE2ACECPA1 | |
| SCHEMBL754129 | 0.92 | MME (0.59) | MMEACE2ACECPA1 | |
| SCHEMBL205548 | 0.92 | MME (0.59) | MMEACE2ACECPA1 | |
| SCHEMBL627437 | 0.92 | MME (0.59) | MMEACE2ACECPA1 | |
| Benzene SCHEMBL27569477 | 0.92 | MME (0.59) | MMEACE2ACECPA1 | |
| SCHEMBL16823433 | 0.88 | HPGDS (0.53) | MMEACE2ACECPA1 | |
| Benzene SCHEMBL28748036 | 0.88 | FOLH1 (0.61) | MMEACE2ACECPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3113780-A1 | HIV PROTEASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2017-01-11 | — | — | EP | disclosed |
| EP-3083609-A1 | HIV PROTEASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2016-10-26 | — | — | EP | disclosed |
| EP-3082822-A1 | HIV PROTEASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2016-10-26 | — | — | EP | disclosed |
| WO-2015134366-A1 | HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-09-11 | — | — | WO | disclosed |
| WO-2015095276-A1 | HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015095265-A1 | HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-06-25 | — | — | WO | disclosed |
| EP-2771332-A1 | HIV PROTEASE INHIBITORS | Merck Canada Inc. (CA) | 2014-09-03 | — | — | EP | disclosed |
| EP-2632895-A1 | HIV PROTEASE INHIBITORS | Merck Canada Inc. (CA) | 2013-09-04 | — | — | EP | disclosed |
| EP-2632908-A1 | SULFONAMIDES AS HIV PROTEASE INHIBITORS | Merck Canada Inc. (CA) | 2013-09-04 | — | — | EP | disclosed |
| WO-2013059928-A1 | HIV PROTEASE INHIBITORS | MERCK CANADA INC. (CA) | 2013-05-02 | — | — | WO | disclosed |
| WO-2012055034-A1 | SULFONAMIDES AS HIV PROTEASE INHIBITORS | MERCK CANADA INC. (CA) | 2012-05-03 | — | — | WO | disclosed |
| WO-2012055031-A1 | HIV PROTEASE INHIBITORS | MERCK CANADA INC. (CA) | 2012-05-03 | — | — | WO | disclosed |